ClinicalTrials.gg
RecruitingNCT06821685Updated Nov 17, 2025

Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History

A Phase 1 interventional study of autologous decidual-like NK cells in Abortion, Habitual, Infertility Unexplained and Embryo Implantation, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Recruiting at 1 site in China. Open to female participants aged 22 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
22 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Abortion, Habitual with a site in China — 4 open to participants now, 4 under way, 1 of them phase 3. Abortion, Habitual · China.

Started
2025
with 1 other
Phase 1
Only one
of the 14
Registered
13th of 14
by date
Lead sponsor
1 of 14
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Among the 14 studies in Abortion, Habitual with a site in China, this one is one of 2 that started in 2025, is the only one in phase 1, and was the 13th registered.

Abortion, Habitual

102 studies on the registry are indexed under Abortion, Habitual; 21 are open to participants now.

Browse Abortion, Habitual studies →

Open to participants now

4 of the 14 studies in Abortion, Habitual with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 15 Abortion, Habitual studies recruiting now, 3 (20%) set no upper age limit and 12 (80%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 22 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Abortion, Habitual with a site in China, or all of them as a file.
02

Study summary

The aim of this study is preliminary exploration of the effectiveness and duration of autologous decidual-like NK cells therapy in improving uterine NK cells dysfunction.

Read the detailed description

Menstrual blood analysis will be performed on patients with infertility or a history of adverse pregnancy outcomes who have fertility needs. Those with abnormal uterine NK cells function will be screened and given informed consent forms pre-treatment. Collecting peripheral blood from the patients, isolating and inducing in vitro culture to obtain autologous decidual like NK cells which will be perfused into their uterine. Perform continuous menstrual blood analysis within 6 months after the first treatment to assess the improvement of uterine NK cell function. If the function of uterine NK cells improves, enter the stage of attempting pregnancy and follow up pregnancy outcomes; If the function of uterine NK cells does not improve, then autologous decidual like NK cells uterine cavity perfusion therapy will be performed again. NK cells intrauterine infusion will be treated up to 2 times.

03

Conditions studied

  • Abortion, Habitual
  • Infertility Unexplained
  • Embryo Implantation
  • Pre-Eclampsia

Keywords

  • recurrent pregnancy loss
  • repeated implantation failure
  • unexplained infertility
  • decidual natural killer cells
04

Who can participate

Ages eligible
22 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • abnormal uterine NK cell function;
  • have one of the following medical history: unexplained recurrent spontaneous abortions (≥2 spontaneous abortions, including biochemical pregnancy), repeated implantation failure (failure of implantation of good-quality embryos in at least two IVF cycles), unexplained infertility, early-onset severe gestational hypertension or early-onset fetal growth restriction;
  • have clear fertility desires;
  • normal ovarian function or with frozen embryos;
  • edometrium thickness measured by vaginal ultrasound before ovulation or at mid-luteal phase >= 7mm;
  • 18kg/m\^2 \< \< 30kg/m\^2;

Exclusion criteria

Exclusion Criteria:

  • using progesterone receptor modulator;
  • chromosomal karyotype abnormalities in one spouse;
  • severe endometriosis, uterine fibroids affecting the shape of the uterine cavity or the size of the whole uterus more than 2 and a half months of pregnancy, uterine malformation, uterine adhesion or thin endometrium;
  • uncontrolled diseases;
  • abnormal blood coagulation function, abnormal liver and kidney function, or other uncontrolled basic diseases (hypertension, diabetes, thyroid disease, etc.) that the researcher access which may affect the progress of the study;
  • history of pelvic malignant tumors;
  • currently participating in other clinical studies;
  • allergic to blood products.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    autologous decidual-like NK cells

    Autologous decidual like NK cells will be isolated and induced in vitro culture from the patients' peripheral blood and perfused into their uterine.

    Biological: autologous decidual-like NK cells

Interventions

  • Biologicalautologous decidual-like NK cells

    intrauterine infusion

06

What researchers measure

Primary outcomes

  1. Improvement rate of NK cells

    Improvement rate of NK cells in menstrual blood of patients after intrauterine infusion of autologous decidual like NK cells

    Time frame: 6 months after the first intrauterine infusion therapy

Secondary outcomes

  1. Duration of improvement in NK cells

    Duration of improvement in NK cells in menstrual blood of patients after intrauterine infusion of autologous decidual like NK cells

    Time frame: 6 months after the first intrauterine infusion therapy

  2. Clinical pregnancy

    Ultrasound indicates the presence of a gestational sac and fetal heartbeat in the uterine cavity

    Time frame: 1 year after completion of NK cells therapy

  3. Ongoing pregnancy

    At least 12 weeks of pregnancy, ultrasound indicates that the fetus has cardiac activity and the size of the fetus matches the gestational age

    Time frame: 1 year after completion of NK cells therapy

  4. Live birth

    Delivery of any number of neonates born at 26 or more weeks' gestation with signs of life

    Time frame: 1 year after completion of NK cells therapy

  5. preeclampsia

    The occurrence of preeclampsia during successful ongoing pregnancy after cell therapy

    Time frame: 1 year after completion of NK cells therapy

  6. fetal growth restriction

    The occurrence of fetal growth restriction during successful ongoing pregnancy after cell therapy

    Time frame: 1 year after completion of NK cells therapy

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Jul 2027, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 12, 2025
StartActual
Feb 13, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2027
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06821685
Collaborators
The University of Science and Technology of China
Responsible party
Sponsor
First posted
Feb 12, 2025
Start date
Feb 13, 2025
Primary completion
Jul 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

Yali Hu
Contact
glyyhuyali@163.com
86-025-83106666 ext. 11201
Hui Zhu
Contact
zhuhui1231@126.com
86-025-83106666 ext. 54330
Yali Hu
principal investigator · The Affiliated Drum Tower Hospital of Nanjing University
Hui Zhu
principal investigator · The Affiliated Drum Tower Hospital of Nanjing University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion